Blood products and pharmaceuticals company CSL saw vincenzo italiano their profit for the first half year fall eight per cent to $US1.62 billion as the result of one-off costs associated with its $16 billion takeover of Swiss company Vifor Pharma.
Without those costs, profit would have been ahead 10 per cent to android $1.82 billion.
It's also the final result from Chief Executive Paul Perreault bruno vespa - who has headed the company for almost 10 years, where CSL shares have increased more than three-and-a-half times.
